About Immune Design (NASDAQ:IMDZ)
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMDZ
CUSIPN/A
Phone650-392-8350
Debt
Debt-to-Equity RatioN/A
Current Ratio10.55%
Quick Ratio10.50%
Price-To-Earnings
Trailing P/E Ratio-2.09
Forward P/E Ratio-2.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.20 million
Price / Sales24.40
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book1.26
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-51,860,000.00
Net Margins-720.81%
Return on Equity-57.56%
Return on Assets-49.08%
Miscellaneous
Employees56
Outstanding Shares48,130,000
Immune Design (NASDAQ:IMDZ) Frequently Asked Questions
What is Immune Design's stock symbol?
Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."
How were Immune Design's earnings last quarter?
Immune Design Corp (NASDAQ:IMDZ) posted its quarterly earnings data on Wednesday, March, 14th. The biotechnology company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.10. The biotechnology company earned $0.49 million during the quarter, compared to analysts' expectations of $0.81 million. Immune Design had a negative return on equity of 57.56% and a negative net margin of 720.81%. View Immune Design's Earnings History.
When is Immune Design's next earnings date?
What price target have analysts set for IMDZ?
4 brokerages have issued twelve-month target prices for Immune Design's stock. Their predictions range from $8.00 to $20.00. On average, they anticipate Immune Design's share price to reach $12.6667 in the next year. View Analyst Ratings for Immune Design.
Who are some of Immune Design's key competitors?
Some companies that are related to Immune Design include Kadmon (KDMN), Merus (MRUS), Seres Therapeutics (MCRB), AVEO Pharmaceuticals (AVEO), Zymeworks (ZYME), Aquinox Pharmaceuticals (AQXP), Catalyst Biosciences (CBIO), BioSpecifics Technologies (BSTC), Celyad (CYAD), Arbutus Biopharma (ABUS), Avadel Pharmaceuticals (AVDL), Savara (SVRA), Selecta Biosciences (SELB), Syndax Pharmaceuticals (SNDX), Minerva Neurosciences (NERV), ArQule (ARQL), Ardelyx (ARDX) and Kindred Biosciences (KIN).
Who are Immune Design's key executives?
Immune Design's management team includes the folowing people:
- Edward E. Penhoet Ph., D., Independent Chairman of the Board (Age 77)
- Carlos V. Paya M.D., Ph.D., President, Chief Executive Officer, Director (Age 58)
- Stephen R. Brady J.D., Executive Vice President, Strategy & Finance (Age 47)
- Sergey Yurasov M.D., Ph.D., Senior Vice President, Clinical Development, and Chief Medical Officer (Age 48)
- Jan Henrik Ter Meule M.D., Chief Scientific Officer (Age 54)
- Melanie Morrison, Vice President - Oncology Platform Leader
- Heidi Petersen, Vice President - Regulatory Affairs
- Wayne R. Gombotz Ph.D., Chief Development Officer (Age 57)
- David Baltimore Ph.D., Independent Director (Age 79)
- Franklin M. Berger, Independent Director (Age 67)
Has Immune Design been receiving favorable news coverage?
News headlines about IMDZ stock have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immune Design earned a news sentiment score of 0.10 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.62 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Immune Design?
Shares of IMDZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Design's stock price today?
One share of IMDZ stock can currently be purchased for approximately $3.65.
How big of a company is Immune Design?
Immune Design has a market capitalization of $178.06 million and generates $7.20 million in revenue each year. The biotechnology company earns $-51,860,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 56 workers across the globe.
How can I contact Immune Design?
Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 650-392-8350 or via email at [email protected]
MarketBeat Community Rating for Immune Design (IMDZ)
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe IMDZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Immune Design (NASDAQ:IMDZ) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Immune Design in the last 12 months. Their average twelve-month price target is $12.6667, suggesting that the stock has a possible upside of 247.03%. The high price target for IMDZ is $20.00 and the low price target for IMDZ is $8.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.6667 | $12.6667 | $16.00 | $16.00 |
| Price Target Upside: | 247.03% upside | 224.79% upside | 332.43% upside | 58.42% upside |
Immune Design (NASDAQ:IMDZ) Consensus Price Target History
Immune Design (NASDAQ:IMDZ) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Immune Design (NASDAQ:IMDZ) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Immune Design (NASDAQ IMDZ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.70%
Institutional Ownership Percentage: 53.79%
Immune Design (NASDAQ IMDZ) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/8/2018 | Leo Guthart | Major Shareholder | Buy | 20,000 | $3.90 | $78,000.00 | |  |
| 1/5/2018 | Carlos V Paya | CEO | Sell | 7,970 | $4.17 | $33,234.90 | 114,560 | |
| 1/5/2018 | Meulen Jan Henrik Ter | Insider | Sell | 1,986 | $4.17 | $8,281.62 | 41,020 | |
| 1/5/2018 | Stephen R Brady | EVP | Sell | 3,328 | $4.17 | $13,877.76 | 50,490 | |
| 1/4/2018 | Sergey Yurasov | VP | Sell | 675 | $4.17 | $2,814.75 | 28,000 | |
| 11/2/2017 | Lewis W Coleman | Director | Buy | 50,000 | $4.50 | $225,000.00 | | |
| 10/30/2017 | Franklin M Berger | Director | Buy | 25,000 | $4.58 | $114,500.00 | 75,000 | |
| 10/27/2017 | Leo Guthart | Major Shareholder | Buy | 2,439,000 | $4.10 | $9,999,900.00 | | |
| 10/27/2017 | Peter Svennilson | Director | Buy | 2,681,000 | $4.10 | $10,992,100.00 | | |
| 10/25/2017 | Franklin M Berger | Director | Buy | 25,000 | $4.26 | $106,500.00 | 50,000 | |
| 10/24/2017 | Leo Guthart | Major Shareholder | Buy | 60,000 | $4.65 | $279,000.00 | | |
| 10/19/2017 | Leo Guthart | Major Shareholder | Buy | 10,000 | $6.09 | $60,900.00 | | |
| 9/18/2017 | Leo Guthart | Major Shareholder | Buy | 10,000 | $9.70 | $97,000.00 | | |
| 8/1/2017 | Wayne Gombotz | Insider | Sell | 10,000 | $11.43 | $114,300.00 | 33,054 | |
| 7/11/2017 | Lewis W Coleman | Director | Buy | 12,000 | $9.05 | $108,600.00 | 40,000 | |
| 7/10/2017 | Lewis W Coleman | Director | Buy | 10,000 | $9.00 | $90,000.00 | 40,000 | |
| 7/7/2017 | Lewis W Coleman | Director | Buy | 8,000 | $9.27 | $74,160.00 | 40,000 | |
| 1/4/2017 | Carlos V Paya | Insider | Sell | 3,940 | $5.35 | $21,079.00 | 72,000 | |
| 1/4/2017 | Stephen R Brady | EVP | Sell | 1,642 | $5.35 | $8,784.70 | 32,132 | |
| 12/22/2016 | Lewis W Coleman | Director | Sell | 10,000 | $6.20 | $62,000.00 | 40,000 | |
| 12/16/2016 | Franklin M Berger | Director | Sell | 50,000 | $6.55 | $327,500.00 | 25,000 | |
| 9/20/2016 | Group L P Column | Major Shareholder | Buy | 800,000 | $6.25 | $5,000,000.00 | | |
| 9/20/2016 | Lewis W Coleman | Director | Buy | 40,000 | $6.25 | $250,000.00 | 50,000 | |
| 7/15/2016 | Stephen R Brady | EVP | Buy | 1,500 | $6.84 | $10,260.00 | 17,132 | |
| 11/23/2015 | Wayne Gombotz | insider | Sell | 5,000 | $20.00 | $100,000.00 | 34 | |
| 9/14/2015 | Wayne Gombotz | insider | Sell | 5,000 | $16.19 | $80,950.00 | 34 | |
| 8/25/2015 | Lewis W Coleman | Director | Buy | 3,000 | $14.50 | $43,500.00 | 10,000 | |
| 5/12/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 177,607 | $21.60 | $3,836,311.20 | | |
| 4/24/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 82,892 | $26.81 | $2,222,334.52 | | |
| 4/21/2015 | Franklin M Berger | Director | Buy | 25,000 | $26.50 | $662,500.00 | | |
| 4/21/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 45,820 | $26.51 | $1,214,688.20 | | |
| 4/16/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 53,914 | $28.23 | $1,521,992.22 | | |
| 4/7/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 7,495 | $26.72 | $200,266.40 | | |
| 3/25/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 18,156 | $27.64 | $501,831.84 | | |
| 3/23/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 44,464 | $27.52 | $1,223,649.28 | | |
| 3/18/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 50,309 | $26.09 | $1,312,561.81 | | |
| 3/12/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 129,342 | $24.94 | $3,225,789.48 | | |
| 3/9/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 39,446 | $25.45 | $1,003,900.70 | | |
| 7/29/2014 | Alta Partners Viii, L.P. | Major Shareholder | Buy | 299,559 | $12.00 | $3,594,708.00 | | |
| 7/29/2014 | Franklin M Berger | Director | Buy | 50,000 | $12.00 | $600,000.00 | | |
(Data available from 1/1/2013 forward)
Immune Design (NASDAQ IMDZ) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report?
finance.yahoo.com - April 13 at 5:37 PM |
 | Immune Design (IMDZ) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM |
| ValuEngine Lowers Immune Design (IMDZ) to Sell
www.americanbankingnews.com - April 8 at 11:49 AM |
| Immune Design Corp (IMDZ) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 2 at 1:30 AM |
| Immune Design (IMDZ) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 12:34 PM |
| Immune Design Corp (NASDAQ:IMDZ): Earnings To Drop Next Year, Is It A Long-Term Trend?
finance.yahoo.com - March 22 at 8:20 AM |
| Jefferies Group Weighs in on Immune Design Corp's Q1 2018 Earnings (IMDZ)
www.americanbankingnews.com - March 19 at 1:40 AM |
| Immune Design reports 4Q loss - Yahoo Finance
finance.yahoo.com - March 17 at 8:20 AM |
| Immune Design Corp to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (IMDZ)
www.americanbankingnews.com - March 16 at 4:20 PM |
 | Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 16 at 8:13 AM |
| Immune Design's (IMDZ) "Buy" Rating Reaffirmed at Jefferies Group
www.americanbankingnews.com - March 15 at 5:46 PM |
| Immune Design (IMDZ) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 14 at 7:56 PM |
 | Immune Design Corp. to Host Earnings Call
www.baystreet.ca - March 14 at 7:12 PM |
| Interested In Immune Design Corp (NASDAQ:IMDZ)? Here’s How It Performed Recently
finance.yahoo.com - March 14 at 7:12 PM |
| Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 7:12 PM |
| $810,000.00 in Sales Expected for Immune Design Corp (IMDZ) This Quarter
www.americanbankingnews.com - March 14 at 5:02 AM |
| Immune Design (IMDZ) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 13 at 7:28 PM |
 | Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development
www.bizjournals.com - March 13 at 7:22 PM |
 | When Corporate Social Responsibility Veers Into Political Action: Safe Or Sorry?
www.forbes.com - March 13 at 7:22 PM |
 | Immune Design (IMDZ) Announces Data Update for Lead Immunotherapy Programs
www.streetinsider.com - March 12 at 6:44 PM |
| Immune Design (IMDZ) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 12 at 3:14 PM |
| Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
finance.yahoo.com - March 12 at 8:35 AM |
| Immune Design (IMDZ) to Release Earnings on Wednesday
www.americanbankingnews.com - March 8 at 9:47 AM |
| Immune Design Corp (IMDZ) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 8 at 1:24 AM |
| Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - March 7 at 8:12 AM |
| Analyzing Immune Design (IMDZ) & Achaogen (AKAO)
www.americanbankingnews.com - March 5 at 11:36 AM |
 | What's Happening With These Biotech Stocks? -- Illumina, Immune Design, ImmunoCellular Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - February 28 at 8:13 AM |
| What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
www.nasdaq.com - February 27 at 5:58 PM |
| What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
finance.yahoo.com - February 27 at 8:14 AM |
| Analysts Expect Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - February 25 at 3:48 AM |
| Immune Design Corp (IMDZ) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 11 at 1:28 AM |
| Immune Design to Present at Upcoming Investor Conferences
finance.yahoo.com - February 9 at 9:21 AM |
| Brokerages Expect Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - February 8 at 3:56 AM |
| Analysts Anticipate Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 22 at 4:50 AM |
| -$0.39 Earnings Per Share Expected for Immune Design Corp (IMDZ) This Quarter
www.americanbankingnews.com - January 20 at 5:16 PM |
 | Immune Design: An Attractive Acquisition Target In 2018 - Seeking Alpha
seekingalpha.com - January 19 at 8:04 AM |
| Immune Design Corp (IMDZ) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 17 at 1:48 AM |
| Leo Guthart Purchases 20,000 Shares of Immune Design Corp (IMDZ) Stock
www.americanbankingnews.com - January 10 at 3:38 PM |
| Immune Design Corp (IMDZ) EVP Stephen R. Brady Sells 3,328 Shares
www.americanbankingnews.com - January 9 at 12:46 AM |
| Immune Design Corp (IMDZ) CEO Sells $33,234.90 in Stock
www.americanbankingnews.com - January 9 at 12:46 AM |
| Why Immune Design (IMDZ) Could Beat Earnings Estimates Again - Nasdaq
www.nasdaq.com - January 5 at 1:31 PM |
| Why Immune Design (IMDZ) Could Beat Earnings Estimates Again
finance.yahoo.com - January 5 at 1:31 PM |
| Immune Design Corp (IMDZ) Expected to Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - January 5 at 4:08 AM |
| Immune Design Corp (IMDZ) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - January 3 at 9:44 PM |
| Immune Design (IMDZ) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:44 PM |
| ETFs with exposure to Immune Design Corp. : December 25, 2017
finance.yahoo.com - December 25 at 4:31 PM |
| Immune Design Corp (IMDZ) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 23 at 1:52 AM |
| ETFs with exposure to Immune Design Corp. : December 14, 2017
finance.yahoo.com - December 14 at 4:12 PM |
| Immune Design (IMDZ) Earns Buy Rating from Cowen
www.americanbankingnews.com - December 12 at 1:42 PM |
| Short Interest in Immune Design Corp (IMDZ) Expands By 86.6%
www.americanbankingnews.com - November 29 at 2:38 AM |
Immune Design (NASDAQ:IMDZ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Immune Design (NASDAQ:IMDZ) Income Statement, Balance Sheet and Cash Flow Statement
Immune Design (NASDAQ IMDZ) Stock Chart for Friday, April, 20, 2018
Loading chart…
